Genentech, Inc.

Hoffmann-la Roche Inc.

F. Hoffmann-la Roche Ag

F. Hoffmann-la Roche Sa

Michael Siu

Snahel Patel

Anthony A Estrada

Alan G Olivero

Joseph P Lyssikatos

Bing-Yan Zhu

Jun Liang

Lewis J Gazzard

Rohan V Mendonca

Malcolm Huestis

Bryan K Chan

Timothy Heffron

John Tellis

Steven Huy Do

Joy Drobnick

Terry Kellar

Wen Liu

Daniel P Sutherlin

Andrew Madin

Steven R Magnuson

Eileen Mary Seward

Adrian Folkes

Aleksandr Kolesnikov

Steven T Staben

Richard Pastor

Graham Elgin Jones

Richard A Goldsmith

Sushant Malhotra

Emanuela Gancia

Michael Lainchbury

Craig Stivala

Weiru Wang

Kin Chiu Fong

Tim Heffron

Binqing Wei

Yonghan Hu

Tracy Bayliss

Matthew W Cartwright

Wendy Liu

David Favor

Andrew Good

Paul Goldsmith

Neil Pegg

BinQing Wei

Kevin X Chen

Paul Gibbons

Naomi S Rajapaksa

Aihe Zhou

Daniel Shore

He Haiying

Xiao Yisong

Zheng Jifu

Xu Xing

Zhao Junping

Christopher Hurley

Aijun Lu

Blake Daniels

Baihua Hu

Edna F Choo

Liting Dong

Changyou Ma

Frederick Cohen

Mark Edward Zak

Emily J Hanan

Elisia Villemure

Thomas E Rawson

Cuong Q Ly

Guibai Liang

Samantha Alyson Green

Xianrui Zhao

Matthew Leo Landry

Christian Nilewski

Naomi Rajapaksa

John C Tellis

Kevin Chen

3-Carbonylaminoisoquinoline compounds of formula (I): variations thereof, and their use as inhibitors of HPK1 (hematopoietic kinase 1) are described. The compounds are useful in treating HPK1-dependent disorders and enhancing an immune response. Also described are methods of inhibiting HPK1, methods of treating HPK1-dependent disorders, methods for enhancing an immune response, and methods for preparing the 3-carbonylaminoisoquinoline compounds.

Isoquinoline compounds for the treatment of cancer

Isoquinoline compounds of formula (I): variations thereof, and their use as inhibitors of HPK1 (hematopoietic kinase 1) are described. The compounds are useful in treating HPK1-dependent disorders and enhancing an immune response. Also described are methods of inhibiting HPK1, methods of treating HPK1-dependent disorders, methods for enhancing an immune response, and methods for preparing the isoquinoline compounds.

Isoquinoline compounds and uses thereof

Provided herein are aza-tetracyclic oxazepinyl compounds useful in the treatment of cancers.

Aza-tetracyclic oxazepine compounds and uses thereof

Naphthyridine compounds and uses thereof

3-Carbonylamino-8-aminoisoquinoline compounds of formula (I): variations thereof, and their use as inhibitors of HPK1 (hematopoietic kinase 1) are described. The compounds are useful in treating HPK1-dependent disorders and enhancing an immune response. Also described are methods of inhibiting HPK1, methods of treating HPK1-dependent disorders, methods for enhancing an immune response, and methods for preparing the 3-carbonylamino-8-aminoisoquinoline compounds.

8-aminoisoquinoline compounds and uses thereof

The present invention provides for compounds of Formula I-I and embodiments and salts thereof for the treatment of diseases (e.g., neurodegenerative diseases). R, R, R, X, X, A and Cy variable in Formula I-I all have the meaning as defined herein. 

Biheteroaryl compounds and uses thereof

Naphthyridine compounds and their use as inhibitors of HPK1 are described. The compounds are useful in treating HPK1-dependent disorders and enhancing an immune response. Also described are methods of inhibiting HPK1, methods of treating HPK1-dependent disorders, methods for enhancing an immune response, and methods for preparing the naphthyridine compounds.

Naphthyridines as inhibitors of HPK1

The present invention provides for compounds of Formula I and embodiments and salts thereof for the treatment of diseases (e.g., neurodegenerative diseases). R, R, R, X, X, A and Cy variable in Formula all have the meaning as defined herein.

The invention relates to compounds of formula (I) and salts thereof: wherein ring A and R-Rhave any of the values defined in the specification. The compounds and salts are useful for treating DLK mediated disorders. The invention also provides pharmaceutical compositions comprising a compound of formula (I), or a pharmaceutically acceptable salt thereof, as well as methods of using said compounds, salts, or compositions as DLK inhibitors and for treating neurodegeneration diseases and disorders.

Tricyclic DLK inhibitors and uses thereof

The present invention provides for compounds of Formula (I) and various embodiments thereof, and compositions comprising compounds of Formula (I) and various embodiments thereof.  In compounds of Formula I, the groups R, R, R, R, R, Rand Rhave the meaning as described herein. The present invention also provides for methods of using compounds of Formula I and compositions comprising compounds of Formula (I) as DLK inhibitors and for treating neurodegeneration diseases and disorders.

3-substituted pyrazoles and uses thereof

The present invention provides for compounds of Formula I and embodiments and salts thereof for the treatment of diseases (e.g., neurodegenerative diseases). R, R, R, X, X, A and Cy variable in Formula all have the meaning as defined herein. 

3-substituted pyrazoles and use as DLK inhibitors

A compound of Formula I, enantiomers, diasteriomers, tautomers or pharmaceutically acceptable salts thereof, wherein R, R, R, Rand Rare defined herein, are useful as JAK kinase inhibitors. A pharmaceutical composition that includes a compound of Formula I and a pharmaceutically acceptable carrier, adjuvant or vehicle, and methods of treating or lessening the severity of a disease or condition responsive to the inhibition of JAK kinase activity in a patient are disclosed. 

Triazolopyridine JAK inhibitor compounds and methods

Growing community of inventors

Burlingame, CA, United States of America

Michael Siu